Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
Published . Updated .
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, add
Directly affected
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endp…
Source: Nasdaq Markets
Price since this story was published: Definium Therapeutics (DFTX)
Since the first closing price after “Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study,” Definium Therapeutics (DFTX) is -16.06%. The S&P 500 fund (SPY) is -0.89% over the same days, a -15.16% difference versus the market.
Who gains and who loses around Definium Therapeutics (DFTX)
Companies tied to this story
- DFTX Definium Therapeutics
Definium Therapeutics (DFTX) is linked, with no stored direction, high confidence in the 20 Sep 2026 story “Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study.” Reason on file: The reported development directly names DEFINIUM THERAPEUTICS INC in the headline; GA resolved that company to DFTX
Definium Therapeutics (DFTX)
Definium Therapeutics (DFTX) is the company in “Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study,” the 20 Sep 2026 this story story.
For Definium Therapeutics (DFTX), the reason on file says The reported development directly names DEFINIUM THERAPEUTICS INC in the headline; GA resolved that company to DFTX
Dates in the story, and the Definium Therapeutics (DFTX) price range
DFTX traded between 32.02 and 40.39 across 20 sessions. The latest close on file is 32.96.
A simple score for Definium Therapeutics (DFTX)
14 out of 100
“Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.